2025 United Kingdom Biosimilar Contract Manufacturing Market Revenue Opportunities Report
Description
The 2025 United Kingdom Biosimilar Contract Manufacturing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in the United Kingdom include Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim offers end-to-end biosimilar manufacturing services encompassing mammalian cell cultures and microbial fermentations, aiming to enhance healthcare affordability through strategic partnerships. Lonza and Catalent are major global contract manufacturing organizations with significant capabilities in biologics production, including biosimilars, supporting global pharmaceutical companies by providing scalable manufacturing solutions. Biocon, with facilities in India and Malaysia, focuses on large-scale microbial fermentation as well as mammalian cell culture, serving therapeutic areas like oncology and diabetes, and expanding market access worldwide.
These companies leverage technological advances and global networks to meet growing demand for cost-effective biosimilars, particularly in oncology where biosimilars reduce treatment costs and improve access to monoclonal antibody therapies. Partnerships are common; for example, Boehringer Ingelheim’s collaboration with Quallent Pharmaceuticals expands biosimilar availability, demonstrating the market’s strategic efforts to broaden reach across regions including the UK. Biocon’s investment in cutting-edge manufacturing infrastructure aligns with global standards, allowing for competitive positioning in the UK and international biosimilar markets. Collectively, these companies represent the forefront of biosimilar manufacturing innovation and supply in the UK biosimilar contract manufacturing sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Biosimilar Contract Manufacturing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the biosimilar contract manufacturing market in the United Kingdom include Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza, Catalent, Inc., and Biocon. Boehringer Ingelheim offers end-to-end biosimilar manufacturing services encompassing mammalian cell cultures and microbial fermentations, aiming to enhance healthcare affordability through strategic partnerships. Lonza and Catalent are major global contract manufacturing organizations with significant capabilities in biologics production, including biosimilars, supporting global pharmaceutical companies by providing scalable manufacturing solutions. Biocon, with facilities in India and Malaysia, focuses on large-scale microbial fermentation as well as mammalian cell culture, serving therapeutic areas like oncology and diabetes, and expanding market access worldwide.
These companies leverage technological advances and global networks to meet growing demand for cost-effective biosimilars, particularly in oncology where biosimilars reduce treatment costs and improve access to monoclonal antibody therapies. Partnerships are common; for example, Boehringer Ingelheim’s collaboration with Quallent Pharmaceuticals expands biosimilar availability, demonstrating the market’s strategic efforts to broaden reach across regions including the UK. Biocon’s investment in cutting-edge manufacturing infrastructure aligns with global standards, allowing for competitive positioning in the UK and international biosimilar markets. Collectively, these companies represent the forefront of biosimilar manufacturing innovation and supply in the UK biosimilar contract manufacturing sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
